Vicki Moore, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

WCLC 2023

Cardiovascular Events After ICI Therapy “Common” in Lung Cancer

Vicki Moore, PhD

September 19, 2023

Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.

WCLC 2023

Tepotinib Plus Osimertinib May Provide Chemo-Free Option for NSCLC After First-Line Osimertinib

Vicki Moore, PhD

September 15, 2023

Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.

WCLC 2023

Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC

Vicki Moore, PhD

September 13, 2023

First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.

Female pharmacist giving a tablet bottle to patient

WCLC 2023

Adagrasib Shows “Durable Clinical Benefit” in Advanced KRAS-Mutant NSCLC

Vicki Moore, PhD

September 13, 2023

Adagrasib has shown durable clinical activity in patients with advanced KRAS^G12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.